Literature DB >> 8683039

Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells.

E J Shannon1, F Sandoval.   

Abstract

The effect if thalidomide on tumor necrosis factor alpha (TNF-alpha) produced in vitro by lipopolysaccharide (LPS) stimulated human cells was investigated. In cultures of LPS stimulated human mononuclear cells enriched for adherent cells and in cultures of LPS stimulated human monocytes of the cell line-THP-1, thalidomide enhanced the synthesis of TNF-alpha. When cultures of unfractionated peripheral blood mononuclear cells were stimulated with LPS, thalidomide decreased the synthesis of TNF-alpha. Depending on the type of cells stimulated with LPS in vitro, thalidomide, at concentrations achieved in vivo, can either enhance or suppress the synthesis of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683039     DOI: 10.3109/08923979609007110

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  12 in total

1.  Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice.

Authors:  Renana Baratz; David Tweedie; Vardit Rubovitch; Weiming Luo; Jeong Seon Yoon; Barry J Hoffer; Nigel H Greig; Chaim G Pick
Journal:  J Neurochem       Date:  2011-08-05       Impact factor: 5.372

Review 2.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 3.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.

Authors:  A Tadesse; E J Shannon
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

6.  Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.

Authors:  Colleen Goosen; Timothy J Laing; Jeanetta du Plessis; Theunis C Goosen; Tharaknath B Rao; Gordon L Flynn
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 7.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

8.  A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors.

Authors:  David Tweedie; Weiming Luo; Ryan G Short; Arnold Brossi; Harold W Holloway; Yazhou Li; Qian-sheng Yu; Nigel H Greig
Journal:  J Neurosci Methods       Date:  2009-07-05       Impact factor: 2.390

Review 9.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

Review 10.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.